Mantle Cell Lymphoma | Specialty

Understanding the Heterogeneity of Mantle Cell Lymphoma

January 18th 2019

AHCT Consolidation Improves PFS in Younger Patients With Mantle Cell Lymphoma

January 17th 2019

Within 6 months of receiving induction chemotherapy, consolidation treatment with autologous hematopoietic cell transplantation correlated with a significant improvement in progression-free survival in younger, fit patients with mantle cell lymphoma.

BTK Inhibition Continues to Show Promise in Relapsed/Refractory MCL

January 15th 2019

Krish Patel, MD, discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma

January 15th 2019

The FDA has granted the investigational BTK inhibitor zanubrutinib a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy.

Dr. Patel Discusses Promise of Acalabrutinib in MCL

January 15th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses the promise of acalabrutinib in the treatment of patients with mantle cell lymphoma.

Dr. Wang Discusses Next Steps With Acalabrutinib in MCL

January 12th 2019

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCL

January 11th 2019

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Dr. Patel on Differences Between BTK Inhibitors in MCL

January 9th 2019

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses differences between BTK inhibitors in mantle cell lymphoma (MCL).

Lead Researcher Highlights Latest Acalabrutinib MCL Data

January 8th 2019

Michael Wang, MD, discusses the promise of single-agent acalabrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Wang Discusses Single-Agent Acalabrutinib in MCL

January 8th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy of single-agent acalabrutinib in the treatment of mantle cell lymphoma.

Dr. Dean on FDA Approved Drugs for Patients With Relapsed MCL

January 4th 2019

Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.

Dr. Phillips on Emerging Combination in MCL

December 20th 2018

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses an emerging combination in the treatment of patients with mantle cell lymphoma.

Frontline Bendamustine/Rituximab in MCL Improves Real-World EFS Outcomes

December 20th 2018

The frontline induction treatment of bendamustine and rituximab has improved event-free surviva compared with R-CHOP therapy in patients with mantle cell lymphoma.

Lead Researcher Discusses Acalabrutinib Plus BR in MCL

December 18th 2018

Tycel J. Phillips, MD, discusses the clinical implications of acalabrutinib plus bendamustine and rituximab for patients with mantle cell lymphoma.

Venetoclax Shows Durable Responses in Relapsed/Refractory MCL

December 14th 2018

Single-agent venetoclax (Venclexta) led to durable responses in patients with relapsed/refractory mantle cell lymphoma with a low rate of late-onset toxicities.

Acalabrutinib Regimen Highly Active in MCL

December 13th 2018

Adding the BTK inhibitor acalabrutinib to bendamustine and rituximab induced high overall response rates in both treatment-naive and relapsed/refractory patients with mantle cell lymphoma.

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

December 11th 2018

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

Acalabrutinib Monotherapy Produces Durable Response in Mantle Cell Lymphoma

December 4th 2018

Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma shows that responses are durable with no new safety signals observed.